Evidence map›Paper›PMID 25898365›Full record

ArticlePloS one2015

Dried blood spots for viral load monitoring in Malawi: feasible and effective.

Sarah E Rutstein, Mina C Hosseinipour, Deborah Kamwendo, Alice Soko, Memory Mkandawire, Andrea K Biddle, William C Miller, Morris Weinberger, Stephanie B Wheeler, Abdoulaye Sarr and 6 more

Abstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Dried Blood Spots to Assess Cardiovascular-Kidney-Metabolic Health.Journal of the American Heart Association · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Review
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Sarah E RutsteinDepartment of Health Policy and Management, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States; Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States.
Mina C HosseinipourDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States; University of North Carolina Project, Lilongwe, Malawi.
Deborah KamwendoUniversity of North Carolina Project, Lilongwe, Malawi.
Alice SokoUniversity of North Carolina Project, Lilongwe, Malawi.
Memory MkandawireSchool of Public Health, Loma Linda University, Loma Linda, California, United States.
Andrea K BiddleDepartment of Health Policy and Management, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States.
William C MillerDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States.
Morris WeinbergerDepartment of Health Policy and Management, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States.
Stephanie B WheelerDepartment of Health Policy and Management, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States.
Abdoulaye SarrCenters for Disease Control, Lilongwe, Malawi.
Sundeep GuptaCenters for Disease Control, Lilongwe, Malawi.
Frank ChimbwandiraMinistry of Health, Lilongwe, Malawi.
Reuben MwendaMinistry of Health, Lilongwe, Malawi.
Steve KamizaCollege of Medicine, Blantyre, Malawi.
Irving HoffmanDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States.
Ronald MatayaSchool of Public Health, Loma Linda University, Loma Linda, California, United States.

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM008719 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DARVILLE, TONI, DESHMUKH, MOHANISH P · 1999 to 2023
$15.1M
SUPPORTING THE SCALE-UP HIGH QUALITY HIV CARE AND TREATMENT PROGRAMS IN MALAWI U2GPS001965 · PS · UNIVERSITY OF MALAWI · PI KAMIZA, DR. STEVE · 2009 to 2014
$12.9M
Optimizing HIV Therapy: virological monitoring, adherence & cost-effectivenessF30MH098731 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI RUTSTEIN, SARAH E. · 2012 to 2016
$201k
NCHHSTP CDC HHS U2G PS001965NIGMS NIH HHS T32 GM008719NIMH NIH HHS F30 MH098731
6 · The paper itself

Abstract

objectivesTo evaluate the feasibility and effectiveness of dried blood spots (DBS) use for viral load (VL) monitoring, describing patient outcomes and programmatic challenges that are relevant for DBS implementation in sub-Saharan Africa.

methodsWe recruited adult antiretroviral therapy (ART) patients from five district hospitals in Malawi. Eligibility reflected anticipated Ministry of Health VL monitoring criteria. Testing was conducted at a central laboratory. Virological failure was defined as >5000 copies/ml. Primary outcomes were program feasibility (timely result availability and patient receipt) and effectiveness (second-line therapy initiation).

resultsWe enrolled 1,498 participants; 5.9% were failing at baseline. Median time from enrollment to receipt of results was 42 days; 79.6% of participants received results within 3 months. Among participants with confirmed elevated VL, 92.6% initiated second-line therapy; 90.7% were switched within 365 days of VL testing. Nearly one-third (30.8%) of participants with elevated baseline VL had suppressed (<5,000 copies/ml) on confirmatory testing. Median period between enrollment and specimen testing was 23 days. Adjusting for relevant covariates, participants on ART >4 years were more likely to be failing than participants on therapy 1-4 years (RR 1.7, 95% CI 1.0-2.8); older participants were less likely to be failing (RR 0.95, 95% CI 0.92-0.98). There was no difference in likelihood of failure based on clinical symptoms (RR 1.17, 95% CI 0.65-2.11).

conclusionsDBS for VL monitoring is feasible and effective in real-world clinical settings. Centralized DBS testing may increase access to VL monitoring in remote settings. Programmatic outcomes are encouraging, especially proportion of eligible participants switched to second-line therapy.

Indexed as

Dried Blood Spot TestingDrug MonitoringAdolescentAdultAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountFemaleHIV-1HIV InfectionsHumansMalawiMaleMiddle AgedProspective StudiesRNA, ViralAnti-HIV AgentsRNA, Viral

Identifiers

PMID25898365
PMCPMC4405546

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.